Abstract
Individuals on immunosuppressive (IS) therapy have increased mortality from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and delayed viral clearance may lead to new viral variants. IS therapy reduces antibody responses following coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccination; however, a comprehensive assessment of vaccine immunogenicity is lacking. Here we show that IS therapy reduced neutralizing, binding, and nonneutralizing antibody functions in addition to CD4 and CD8 T-cell interferon-γ responses following COVID-19 mRNA vaccination compared to immunocompetent individuals. Moreover, IS therapy reduced cross-reactivity against SARS-CoV-2 variants. These data suggest that the standard COVID-19 mRNA vaccine regimens will likely not provide optimal protection in immunocompromised individuals.
Keywords: 19 vaccine; 2; COVID; CoV; SARS; T cells; immunocompromised; vaccine immunogenicity.
【저자키워드】 T cells, SARS, COVID, Immunocompromised, CoV, 2, 19 vaccine, vaccine immunogenicity., 【초록키워드】 COVID-19, coronavirus disease, SARS-CoV-2, mRNA vaccination, Coronavirus disease 2019, coronavirus, therapy, antibody, mRNA vaccine, T cells, Antibody Response, Infection, interferon, severe acute respiratory syndrome Coronavirus, CD4, viral clearance, cross-reactivity, Antibody responses, Viral, SARS-CoV-2 variants, mRNA, response, Immunocompromised, Viral variants, Neutralizing, respiratory, function, binding, immunosuppressive, vaccine immunogenicity, regimen, lead, COVID-19 mRNA Vaccination, Messenger RNA, interferon-γ, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, immunocompromised individuals, These data, individual, increased mortality, addition, reduced, reduce, individuals, CD8 T-cell, 【제목키워드】 immunogenicity, RNA, individual, messenger,